Company

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment
J&JJohnson & Johnson

Triastek Partners with Johnson & Johnson to Develop Novel Oral Medicines Using 3D Printing Pharmaceutical Technology – JJDC Makes Strategic Equity Investment

Triastek (Nanjing) Pharmaceutical Technology Co., Ltd. ("Triastek") announced that it has entered into a Collaboration and License Agreement with Johnson & Johnson (J&J, NYSE: JNJ), combining J&J's expertise in drug…

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

Viatris to Acquire Pacira BioSciences for USD 1.65 Billion – Expanding Non‑Opioid Pain Portfolio with EXPAREL and ZILRETTA

FDA Approves Genentech's Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

FDA Approves Genentech’s Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX3902 Trispecific Antibody in Advanced Solid Tumors

Auto-immuneBiogen

Biogen to Acquire Immunology Specialist RayThera in $1 Billion Deal Targeting Anti-Inflammatory Pipeline

Cell-therapyClinical trial approval / initiation

Hopstem Biotechnology Secures FDA Clearance for hNPC01 Neural Progenitor Cell Therapy in Hemorrhagic Stroke Motor Dysfunction

BayerETR: BAYN

Bayer AG Completes $2.45 Billion Acquisition of Perfuse Therapeutics for PER-001 Glaucoma Implant

Show More